Please check your internet connection and try again.
# Miconazole Vaginal Pessary
## Overview
Miconazole vaginal pessary is a broad-spectrum imidazole antifungal agent used for the treatment of vulvovaginal candidiasis (yeast infections). It is available in various strengths and dosage forms.
## Primary Indications
Treatment of vulvovaginal candidiasis caused by *Candida albicans* and other susceptible *Candida* species.
## Adult Dosing
* **100 mg pessary:** Insert one pessary vaginally at bedtime for 7 consecutive days.
* **200 mg pessary:** Insert one pessary vaginally at bedtime for 3 consecutive days.
* **6.5% miconazole nitrate (1 applicatorful) topical cream:** Insert one applicatorful vaginally at bedtime for 7 consecutive days. This is often formulated as a single-dose applicator.
Specific duration of therapy may vary based on formulary guidelines or clinician preference.
## Pediatric Dosing
* **Children 12 years and older:** Use adult dosing.
* **Children younger than 12 years:** Safety and efficacy have not been established. Consult product labeling or local pediatric guidelines.
## Dose Adjustments
No dose adjustments are typically necessary for renal or hepatic impairment, as systemic absorption is minimal.
## Contraindications
* Hypersensitivity to miconazole or any component of the formulation.
* Concurrent use with oral or intravenous miconazole (due to risk of increased systemic exposure and potential for serious drug interactions).
## Adverse Effects
* **Common:** Vulvovaginal burning, itching, irritation, or discomfort; abdominal cramping.
* **Less Common:** Rash, hives, headache.
## Key Drug Interactions
* **CYP3A4 Inhibitors:** Miconazole is a potent inhibitor of CYP3A4. Concurrent use with medications metabolized by CYP3A4 (e.g., warfarin, certain statins, ciclosporin, tacrolimus) can lead to increased plasma concentrations of these drugs, potentially causing serious toxicity. **Avoid concurrent use, or monitor closely for adverse effects and adjust the dose of the co-administered drug if necessary.**
* **CYP2C9 Inhibitors:** Miconazole also inhibits CYP2C9, which can affect the metabolism of drugs like warfarin, leading to an increased risk of bleeding.
* **Oral/IV Miconazole:** Concurrent use is contraindicated.
## Monitoring
* Monitor for signs and symptoms of vaginal infection resolution.
* Monitor for adverse effects, especially local irritation or signs of systemic drug interactions if co-administered with CYP substrates.
## Clinical Pearls
* Advise patients to complete the full course of therapy, even if symptoms improve earlier.
* Inform patients that miconazole vaginal products can damage latex condoms and diaphragms, reducing their effectiveness. Use alternative birth control methods during treatment and for at least 72 hours after treatment completion.
* Symptoms may take a few days to fully resolve even after completing treatment. If symptoms persist or worsen, patients should consult their healthcare provider.
* For recurrent or difficult-to-treat infections, a longer duration of therapy or an alternative antifungal agent may be necessary.
***
**Disclaimer:** This information is intended for clinical decision-making and does not replace the need to consult current product labeling, local protocols, and guidelines. Always verify the most up-to-date prescribing information before administering any medication.
